-
Posted by
Two Blokes Apr 30 -
Filed in
Stock
-
0 views
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs.
